

#### Cystaran (cysteamine) **Effective 01/01/2023** ☐ MassHealth UPPL Plan Prior Authorization □ Commercial/Exchange **Program Type** ☐ Quantity Limit □ Pharmacy Benefit **Benefit** ☐ Step Therapy ☐ Medical Benefit Specialty This medication has been designated specialty and must be filled at a contracted Limitations specialty pharmacy. **Medical and Specialty Medications** Phone: 877-519-1908 All Plans Fax: 855-540-3693 Contact Information **Non-Specialty Medications All Plans** Phone: 800-711-4555 Fax: 844-403-1029 N/A

### Overview

Cysteamine reacts with cystine within the lysosome to convert it to cysteine and to a cysteine-cysteamine mixed disulfide, both of which can then exit the lysosome to reduce corneal cystine crystal accumulation in patients with cystinosis, an inherited defect of lysosomal transport.

#### **Coverage Guidelines**

**Exceptions** 

Authorization may be reviewed on a case by case basis for members new to the plan who are currently receiving treatment with Cystaran excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

- 1. The member has a diagnosis of corneal cystine accumulation with cystinosis
- 2. The provider specialty is an ophthalmologist or drug is being used in consultation with an ophthalmologist.

### **Continuation of Therapy**

Reauthorization requires physician documentation of improvement of member's condition.

#### Limitations

Authorizations will be approved for 24 months

# References

1. Cystaran (cysteamine) [prescribing information]. Gaithersburg, MD: Leadiant Biosciences; February 2022.

## **Review History**

Mass General Brigham Health Plan includes Mass General Brigham Health Plan, Inc. and Mass General Brigham Health Insurance Company.

09/24/2020 – Created and Reviewed Sept P&T Mtg. Effective 11/01/20. 09/21/2022 – Reviewed at Sept P&T; Separated Comm/Exch vs MH policies; no clinical updates. Effective 01/01/2023

